{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:41:44Z","timestamp":1793407304085,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T00:00:00Z","timestamp":1113350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> The study aims to evaluate the efficacy of combination therapy with propylthiouracil (PTU) and cholestyramine in the treatment of Graves\u2019 hyperthyroidism.<\/jats:p><jats:p><jats:bold>Background\u2002<\/jats:bold> Thyroxine (T4) is metabolized mainly in the liver by conjugation to glucuronides and sulphates that enter the enterohepatic circulation. Thyrotoxic patients have an abnormal increase in thyroid hormone in their enterohepatic circulation. Previous studies on combination therapy with methimazole and cholestyramine for Graves\u2019 hyperthyroidism have shown it to be an effective adjunctive treatment. In this study, we examined the efficacy of combination therapy with PTU and cholestyramine in the treatment of Graves\u2019 hyperthyroidism.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Thirty patients with newly diagnosed Graves\u2019 hyperthyroidism were randomly divided into two groups: group I (<jats:italic>n<\/jats:italic>\u00a0=\u00a015) received PTU 100\u00a0mg twice a day, propranolol 40\u00a0mg twice a day and cholestyramine 4 g twice a day for 4\u00a0weeks; group II (<jats:italic>n<\/jats:italic>\u00a0=\u00a015) received PTU 100\u00a0mg twice a day and propranolol 40\u00a0mg twice a day for 4\u00a0weeks. The therapeutic efficacy was determined by serum total triiodothyronine (TT3), free thyroxine (FT4) and TRAb levels at baseline, and at the end of 2 and 4\u00a0weeks during the study period.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> There was no significant difference in baseline thyroid function parameters. At the end of 2 and 4\u00a0weeks of the study period, serum TT3 and FT4 levels of group I were significantly lower than those of group II. No significant differences in the TRAb level were found between the two groups.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Cholestyramine contributed to a more rapid and complete decline in thyroid hormone levels in patients with Graves\u2019 hyperthyroidism. It was thus proved to be an effective and well\u2010tolerated adjunctive therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2005.02249.x","type":"journal-article","created":{"date-parts":[[2005,4,21]],"date-time":"2005-04-21T10:09:33Z","timestamp":1114078173000},"page":"521-524","source":"Crossref","is-referenced-by-count":72,"title":["The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves\u2019 hyperthyroidism"],"prefix":"10.1111","volume":"62","author":[{"given":"Wen\u2010Chin","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tso\u2010Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u2010An","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u2010Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Lian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien\u2010Hsing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng\u2010Pyng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi\u2010Wen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,13]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb00970.x"},{"key":"e_1_2_5_3_2","first-page":"1361","volume-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics.","author":"Haynes R.C.","year":"1990"},{"key":"e_1_2_5_4_2","first-page":"256","article-title":"Influence of cholestyramine on absorption and excretion thyroxine in Syrian hamster","volume":"53","author":"Bergman F.","year":"1996","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.1969.03160100047012","article-title":"The influence of cholestyramine on thyroxine absorption","volume":"208","author":"Northcut R.C.","year":"1969","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-102-25358"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.204.13.1161"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.9.3191"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105857"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-120-30443"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-8-658_2"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-46-5-838"},{"key":"e_1_2_5_13_2","first-page":"126","volume-title":"The Thyroid, a Clinical and Fundmental Text.","author":"Chopra I.J.","year":"1991"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.11.3777"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-1-28"},{"key":"e_1_2_5_16_2","first-page":"1068","article-title":"Total thyroidectomy in therapy\u2010resistant Graves\u2019 disease","volume":"116","author":"Winsa B.","year":"1994","journal-title":"Surgery"},{"key":"e_1_2_5_17_2","first-page":"1108","article-title":"Surgery still has a role in Graves\u2019 hyperthyroidism","volume":"114","author":"Patwardhan N.A.","year":"1993","journal-title":"Surgey"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347940"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.5.1853"},{"key":"e_1_2_5_20_2","first-page":"691","volume-title":"Werner and Ingbar's The Thyroid","author":"Cooper D.S.","year":"2000"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2005.02249.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2005.02249.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:03:16Z","timestamp":1697187796000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2005.02249.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,13]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1365-2265.2005.02249.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02249.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,13]]}}}